Aerska

Private

DublinHealthcare & Life Scienceshttps://www.aerska.com/

Last Round

Series A

May 20, 2026

Total Funding Raised

$119M

Momentum

Top 5%

of companies Caplight tracks

Company Overview

Aerska is a biotechnology company developing RNA interference (RNAi) medicines designed to treat, delay, and prevent diseases of the brain.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Precision Medicine, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting, Government Contracts

AI Layer

Non-AI

Keywords

RNA interferenceRNAi therapyblood-brain barrier deliveryAntibody-Oligonucleotide ConjugateAOC platformgene silencingbrain shuttleCNS drug deliveryneurological disease therapyoligonucleotide therapeuticsgenetic medicinedrug delivery platformAlzheimer's diseaseParkinson's diseasebiopharma partnerships

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Aerska Comps

Public and private peers based on sector, stage, and business model.

Aerska comps — public and private peers by sector, stage, and business model
Company	Status	Est. Valuation	Rev Multiple
OpenAI	Private	$86.0B	~40x
Cohere	Private	$5.0B	--
Competitor 1	Public	$XX.XB	XXx
Competitor 2	Public	$XX.XB	XXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Aerska Funding Rounds

Historical fundraising activity

Data table
Round	Date	Amount Raised	Valuation	Investors	Sources
Series A	May 20, 2026
Series A	Feb 9, 2026
Seed	Oct 2, 2025

View all Funding Rounds

Aerska Investors

Notable investors and investment history

Aerska investors
Investor	Rounds
Iaso Ventures	Series A
Backed VC	Seed
Saras Capital	Seed
Lingotto	Seed
BlueYard Capital	Seed
Ada Ventures	Seed
age1	Series A, Seed

View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

Jun 25, 2026
Grew 35% QoQ, from 20 to 27 employees.
Apr 15, 2026
Lisa Taylor Ash joins the Board of Directors.

View all signals

Aerska Filings

SEC and related filings with document metadata.

Data table
Typed	Date	Amount Offered	Amount Sold	Filling	Pages	Download
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation
Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation	Sign Up to view	Mock Valuation

Aerska Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Aerska's valuation, stock price, and market status.

Firmographic Details

HeadquartersDublin

Employee Range27

Year Founded2025

Last FundingMay 20, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.